Filana Therapeutics adds biopharma executive Jill Quigley to board
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing
3 stories
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing
Shareholders voted on November 5, 2026 to approve the stock issuance, reverse split, and charter changes needed to complete the merger with Remix Therapeutics.
SEC filing
The September 2, 2026 amendment restructures the Remix merger into two sequential mergers and revises how the concurrent private placement can be funded.
SEC filing